Biologic disease-modifying antirheumatic drug

Biologic disease-modifying antirheumatic drug has been studied in 4 papers since 2023: 4 observational studies in people; 3 in the past year. The newest story, Nov 2, 2026: “Arthritis drugs may be linked to lower osteoporosis risk”.

Intervention

4 papers study it2 findingsUpdated Oct 26, 2026

1 new paper in 30 daysSee all 4 papers on biologic disease-modifying antirheumatic drug

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries.

“Hip fracture risk did not differ across groups.”

Comparative Risk of Osteoporosis and Osteoporotic Fractures According to Exposure to 2 Groups of Biologics in Patients With Radiographic Axial SpondyloarthritisThe Journal of rheumatology2026doi:10.3899/jrheum.2025-0988

None of its findings points the other way.

2 independent labs in 2 countries

Funder: Japan Society for the Promotion of Science

Humans4

What did studies of biologic disease-modifying antirheumatic drug find?

Studies of biologic disease-modifying antirheumatic drug measured 1 outcome; the most studied are hip fracture (1 study).

Hip fracture

no changein humans1

1 study

Biologic disease-modifying antirheumatic drug was not clearly linked with hip fracture in humans (Radiographic axial spondyloarthritis; TNFi, IL-17i, and bDMARD-naïve groups).
“Hip fracture risk did not differ across groups.”
HumansRadiographic axial spondyloarthritis; TNFi, IL-17i, and bDMARD-naïve groups
Arthritis drugs may be linked to lower osteoporosis risk
The Journal of rheumatologyMar 3, 2026

What is biologic disease-modifying antirheumatic drug linked with?

Studies link biologic disease-modifying antirheumatic drug with 1 measure, most often sarcopenia (1 study).

Sarcopenia

upin humans1

1 study

Biologic disease-modifying antirheumatic drug is associated with sarcopenia in Japanese patients with RA (P < 0.05).
“use of nonsteroidal anti-inflammatory drugs (NSAIDs), biologic disease-modifying antirheumatic drugs (bDMARDs), and corticosteroids were significantly (P < 0.05) associated with sarcopenia.”
Humansin Japanese patients with RAn = 2,416
Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study
Clinical rheumatologySep 21, 2023

Latest

3 papers in 12 months

ESC Congress 2026 AbstractOct 26

Association of Non-HDL cholesterol with cardiovascular risk and subclinical atherosclerosis in patients with rheumatoid arthritis

Cross-sectional study in peopleNon-HDL cholesterol

Paper

The Journal of RheumatologyMar 3

Arthritis drugs may be linked to lower osteoporosis risk

Compared with no biologic exposure, adjusted osteoporosis hazard ratios—a measure of relative risk—were 0.83 for tumor necrosis factor inhibitors and 0.19 for…Compared with no biologic exposure, adjusted osteoporosis hazard ratios—a measure of relative risk—were 0.83 for tumor necrosis factor inhibitors and 0.19 for interleukin-17 inhibitors.

Cohort · 37,708 peopleOsteoporosis